Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
genetic diseases
Biotech
Chiesi fertilizes Arbor's gene therapy with $2B biobucks deal
Chiesi is shelling out $115 million upfront to develop and commercialize ABO-101, a gene therapy for primary hyperoxaluria type 1.
Darren Incorvaia
Oct 6, 2025 7:00am
Servier supercharges neuro pipeline with $450M deal
Sep 8, 2025 2:30am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
RNA biotech emerges with $52M and clinical rare disease asset
Aug 25, 2025 10:13am
Cash-strapped Sangamo seeks partner for new gene therapy
Jun 24, 2025 11:53am
Rocket's gene therapy sets new efficacy bar in ph. 1 heart study
May 16, 2025 10:36am
